Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy

Diabetologia

Volumn 45, Issue 2, 2002, Pages 203-209

  Hogeboom Van Buggenum, I M ^a   Polak, B C P ^a   Reichert Thoen, J W M ^a   De Vries Knoppert, W A E J ^a   Van Hinsbergh, V W M ^a,b   Tangelder, G J ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive agents; Diabetes mellitus; Diabetic retinopathy; Enalapril; Patients; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VASCULOTROPIN;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; EYE SURGERY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; SYSTOLIC BLOOD PRESSURE; VITREOUS BODY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENALAPRIL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; LYMPHOKINES; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 0036190235     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-001-0747-8     Document Type: Conference Paper

References (41)

1. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
2. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
3. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy
4. Mechanisms of retinal and choroidal neovascularization
5. Intraocular neovascularization
6. Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues
7. Advanced glycation end products increase retinal vascular endothelial growth factor expression
8. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
9. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and supressed by an orally effective β-isoform-selective inhibitor
10. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
11. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
12. Renin-containing Muller cells of the retina display endocrine features
13. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy
14. Angiotensin levels in the eye
15. Plasma prorenin activity and complications in children with insulin-dependent diabetes melitus
16. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells
17. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 alpha in vascular smooth muscle cells
18. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
19. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells
20. Angiotensin II-stimulated vascular growth factor expression in bovine retinal pericytes
21. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
22. Methodology for retinal photography and assessment of diabetic retinopathy: The EURODIAB IDDM Complications Study
23. Retinal neovascularization is prevented by blockade of the renin-angiotensin system
24. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells
25. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
26. Cardiovascular and metabolic benefits of ACE inhibition: Moving beyond blood pressure reduction
27. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
28. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension
29. Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction
30. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
31. Angiotensin converting enzyme inhibitor treatment for young normotensive diabetic subjects: A two-year trial
32. Protective effect of captopril on the blood retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy
33. Can diabetic neuropathy be prevented by angiotensin converting enzyme inhibitors?
34. Role of vascular endothelial growth factor in diabetic nephropathy
35. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
36. Capillary permeability is increased in normo- and microalbuminuric type 1 diabetic patients: Amelioration by ACE-inhibition
37. Effect of angiotensin-converting enzyme inhibition with perindopril and betablockade with atenolol on retinal blood flow in hypertensive diabetic subjects
38. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: A potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy
39. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenetic activity in retinal microcapillary endothelial cells